Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...

1-lineage variants of omicron rather than the XBB.1.5 omicron variant. This is akin to a strain change for a seasonal ...

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

On July 3, 2024, BioNTech and Pfizer’s Omicron JN.1-adapted COVID-19 vaccine was approved by the European Commission (“EC”). Shortly following approval, the updated vaccines were made ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million.

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $150.00. Robert Burns has ...

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Este artículo estará disponible en español en El Tiempo Latino. Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...